A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies
Millie Das, Sukhmani K. Padda, Adam Frymoyer, Julian Molina, Alex Adjei, Janet L. Lensing, Dale Miles, Branimir I. Sikic, Heather A. Wakelee
Dive into the research topics of 'A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies'. Together they form a unique fingerprint.